C. Russell Trenary III - 06 Jul 2021 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
CEO and President, Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol
OTLK
Transactions as of
06 Jul 2021
Net transactions value
$0
Form type
4
Filing time
08 Jul 2021, 17:26:26 UTC
Next filing
02 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +4,000,000 $0.000000 4,000,000 06 Jul 2021 Common Stock 4,000,000 $2.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on July 6, 2022, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date. The option is also subject to acceleration under certain circumstances.